Transplant or No Transplant for Mutated AML

Overview

Journal Oncotarget

Specialty Oncology

Date 2024 Oct 1

PMID 39352794

Authors

Talha Badar

Moazzam Shahzad

Ehab Atallah

Mark R Litzow

Mohamed A Kharfan-Dabaja

Affiliations

Soon will be listed here.

References

Stelljes M, Middeke J, Bug G, Wagner-Drouet E, Muller L, Schmid C . Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial. Lancet Haematol. 2024; 11(5):e324-e335. DOI: 10.1016/S2352-3026(24)00065-6. View

Loke J, Labopin M, Craddock C, Cornelissen J, Labussiere-Wallet H, Wagner-Drouet E . Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia. Cancer. 2022; 128(15):2922-2931. PMC: 9545190. DOI: 10.1002/cncr.34268. View

Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik V, Paschka P, Roberts N . Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016; 374(23):2209-2221. PMC: 4979995. DOI: 10.1056/NEJMoa1516192. View

Boyiadzis M, Zhang M, Chen K, Abdel-Azim H, Abid M, Aljurf M . Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients. Leukemia. 2022; 37(5):1006-1017. PMC: 10148918. DOI: 10.1038/s41375-022-01738-3. View

Daver N, Maiti A, Kadia T, Vyas P, Majeti R, Wei A . TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions. Cancer Discov. 2022; 12(11):2516-2529. PMC: 9627130. DOI: 10.1158/2159-8290.CD-22-0332. View

Badar T, Atallah E, Shallis R, Saliba A, Patel A, Bewersdorf J . Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia. 2023; 37(4):799-806. DOI: 10.1038/s41375-023-01847-7. View

Badar T, Nanaa A, Atallah E, Shallis R, Guilherme S, Goldberg A . Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood Cancer J. 2024; 14(1):32. PMC: 10879201. DOI: 10.1038/s41408-024-01000-2. View

Baron F, Labopin M, Niederwieser D, Vigouroux S, Cornelissen J, Malm C . Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia. 2012; 26(12):2462-8. DOI: 10.1038/leu.2012.135. View

Grob T, Al Hinai A, Sanders M, Kavelaars F, Rijken M, Gradowska P . Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2022; 139(15):2347-2354. PMC: 11022827. DOI: 10.1182/blood.2021014472. View

10.

Bejanyan N, Weisdorf D, Logan B, Wang H, Devine S, de Lima M . Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant. 2014; 21(3):454-9. PMC: 4329076. DOI: 10.1016/j.bbmt.2014.11.007. View

11.

Badar T, Nanaa A, Atallah E, Shallis R, Craver E, Li Z . Prognostic impact of 'multi-hit' <i>versus</i> 'single-hit' <i>TP53</i> alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases. Haematologica. 2024; 109(11):3533-3542. PMC: 11532685. DOI: 10.3324/haematol.2024.285000. View

12.

Badar T, Atallah E, Shallis R, Goldberg A, Patel A, Abaza Y . Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. Am J Hematol. 2022; 97(7):E232-E235. DOI: 10.1002/ajh.26546. View

13.

Ciurea S, Chilkulwar A, Saliba R, Chen J, Rondon G, Patel K . Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with mutations. Blood. 2018; 131(26):2989-2992. PMC: 7218750. DOI: 10.1182/blood-2018-02-832360. View